Clinical Notes AI's AI-powered platform uses over 25 different AI models to generate highly complex behavioral healthcare ...

There are benefits and risks to every potential path forward, in terms of outcomes, unintended consequences of treatment ... One is to try to find all of the related information that exists in ...

Shuttle Pharmaceuticals (NASDAQ: SHPH), a rising force in cancer treatment innovation, has experienced a notable boost in its ...

The company's CEO, James Dentzer, expressed optimism about the progress of Curis's clinical programs and the ... emavusertib. In terms of analyst ratings, H.C. Wainwright adjusted its outlook ...

In its third quarter of 2024 financial report, Tyra Biosciences highlighted significant progress in its clinical trials and corporate development. The company reported positive interim results for ...

Yaron Werber has given his Buy rating due to a combination of factors, primarily the promising progress and outcomes of IO Biotech’s clinical trials. The company’s Phase 3 melanoma study is on ...

Unfortunately, I don’t see major near-term catalysts that could justify a bullish rating at this stage. Similarly, by the ...

GE HealthCare's AI initiatives, including AI-powered imaging solutions and strategic partnerships, are led by its chief AI ...

Tyra Bioscience, Inc ( (TYRA)) has released its Q3 earnings. Here is a breakdown of the information Tyra Bioscience, Inc presented to its investors. Tyra Biosciences, Inc. is a clinical-stage ...

The company reported a strong cash position, which is expected to fund operations into late 2026, and emphasized the progress made in its clinical programs, including the completion of enrollment ...

Research studies explore the different factors that affect health and lead to disease. Clinical trials test the safety and effectiveness of new cancer drugs and treatments. They help us find better ...